Gefticip (Gefitinib) 250 mg Tablet is a targeted cancer therapy widely used in the treatment of non-small cell lung cancer (NSCLC). It works by blocking specific proteins that drive cancer cell growth and division. Gefitinib belongs to the class of epidermal growth factor receptor (EGFR) inhibitors, making it an effective choice for patients whose tumors have EGFR mutations. According to Mayo Clinic and FDA, targeted therapies like Gefitinib provide advanced treatment options with improved outcomes compared to conventional chemotherapy.

Key Benefits & Uses

• Used for treating non-small cell lung cancer (NSCLC).

• Targets and blocks EGFR mutations responsible for cancer growth.

• Offers a personalized treatment approach for selected patients.

• May help improve progression-free survival in EGFR-positive lung cancer.

• Recommended by cancer specialists and approved by the FDA.

For more detailed insights, visit Drugs.com and WebMD.

How to Use

• Dosage: Typically, one tablet (250 mg) daily or as directed by your oncologist.

• Can be taken with or without food.

• Take at the same time each day for best results.

• Do not stop or change the dose without consulting your doctor.
  Guidance on safe medication use is available on Healthline.

Important Safety Information

• Inform your doctor if you have liver, kidney, or lung conditions.

• Not recommended during pregnancy or breastfeeding.

• Avoid grapefruit products, as they may interfere with Gefitinib’s effectiveness.

• Regular monitoring and lab tests are required during treatment.
  Learn more about safety at WHO and PubMed.

Common Side Effects

According to WebMD and Drugs.com, common side effects include:

• Diarrhea

• Skin rash or acne

• Loss of appetite

• Nausea and vomiting

• Weakness or fatigue

Seek immediate medical help if you experience severe lung issues, vision problems, or liver-related symptoms.

Why Choose Gefticip (Gefitinib) 250 mg Tablet?

• A trusted EGFR inhibitor for lung cancer treatment.

• Backed by clinical research published in PubMed.

• Recommended by leading health organizations including the WHO.

• Provides a targeted, less invasive treatment option compared to chemotherapy.